S. N. Gallicchio

发表

Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.

A. D. Rodrigues, E S Walsh, J B Gibbs, 2001, Journal of medicinal chemistry.

Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction

P. Coleman, Christopher D. Cox, D. Klein, 2021, ACS medicinal chemistry letters.

Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

J. Vacca, C. Regan, Y. S. Tang, 2010, Journal of Pharmacology and Experimental Therapeutics.

Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.

S. Stirdivant, L. Kuo, P. Darke, 2005, Biochemistry.

Identification of a novel RAMP-independent CGRP receptor antagonist.

J. Vacca, S. Graham, R. Z. Rutledge, 2011, Bioorganic & medicinal chemistry letters.

[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.

Sandra M. Sanabria-Bohórquez, L. Gantert, E. Hostetler, 2013, ACS medicinal chemistry letters.

MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.

J. Vacca, H. Selnick, S. Graham, 2012, Bioorganic & medicinal chemistry letters.

Efficient synthesis of 1-heterocyclic-3-aminopyrrolidinones

T. Williams, I. M. Bell, S. N. Gallicchio, 2000 .

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

B. E. Evans, M A Jacobson, M. Bock, 1999, Bioorganic & medicinal chemistry letters.

Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, J. Hochman, 2006, Bioorganic & medicinal chemistry letters.

The discovery of highly potent CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2009, Bioorganic & medicinal chemistry letters.

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

A. D. Rodrigues, J Christopher Culberson, Ronald Robinson, 2002, Journal of medicinal chemistry.

Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.

J. Vacca, P. Kunapuli, S. Graham, 2006, Bioorganic & medicinal chemistry letters.

In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232

Sandra M. Sanabria-Bohórquez, G. Bormans, L. Gantert, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

S Vickers, R. Freidinger, D. Reiss, 1998, Journal of medicinal chemistry.

Identification of potent, highly constrained CGRP receptor antagonists.

Steven S. Sharik, Cory R. Theberge, J. Vacca, 2010, Bioorganic & medicinal chemistry letters.

Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.

J. Vacca, C. Regan, T. Prueksaritanont, 2010, ACS medicinal chemistry letters.

The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2009, Bioorganic & medicinal chemistry letters.